LONDON: British pharmaceuticals giant GlaxoSmithKline (GSK) has agreed to a $350-million deal with Adaptimmune to help develop and sell the biotechnology firm’s cancer drugs, the companies said on Monday.
Adaptimmune announced in a statement that it has entered a “strategic cancer immunotherapy collaboration” with GSK to “develop and commercialize novel cell-based therapies” in its lead clinical cancer program.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.